- Conditions
- Insomnia Chronic, Posttraumatic Stress Disorder
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–37
of 37
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin, Quetiapine
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
- Conditions
- Major Depressive Disorder
- Interventions
- Psilocybin, Pimavanserin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia
- Interventions
- Pimavanserin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- pimavanserin tartrate (ACP-103)
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Danbury, Connecticut
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Interventions
- ACP-103
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 13
- States / cities
- Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more
- Conditions
- Intermittent Explosive Disorder
- Interventions
- Pimavanserin 34 mg, Placebo
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Interventions
- Pimavanserin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Costa Mesa, California • Santa Ana, California + 13 more
- Conditions
- Schizophrenia
- Interventions
- Pimavanserin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more
- Conditions
- Agitation and Aggression in Alzheimer's Disease
- Interventions
- Pimavanserin 34 mg, Pimavanserin 20 mg, Placebo
- Drug · Other
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 33
- States / cities
- Costa Mesa, California • Fresno, California • Fullerton, California + 30 more
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Parkinson's Disease
- Interventions
- Pimavanserin, Placebo, Quetiapine
- Drug · Other
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more